TrialLeukemia2020

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.

Georg Lenz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.